visualizations
Zakari, Ahmed, MD
Overview
overview
- Ahmed Zakari, MD, is board-certified in internal medicine, hematology and oncology physician. He was named Chief Fellow at Georgetown University Medical Center, Washington, DC, and is a recipient of the Golden Apple “Best Teacher”Award at Georgetown Medical School. His thesis, “Traumatic Rupture of the Thoracic Aorta,” received honors from all members of the jury. Dr. Zakari is a member of the American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH) and National Arab American Medical Association (NAAMA). Dr. Zakari also serves as the Associate Professor of Internal Medicine at the UCF College of Medicine. He is fluent in Arabic, English and French.
Affiliation
Member of
-
Research Department
Publications
Most Recent Publications
-
2024Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study.. JOURNAL OF CLINICAL ONCOLOGY. 9-9.Full Text via DOI: 10.1200/JCO.2024.42.3_suppl.9
-
2020Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. LANCET GASTROENTEROLOGY & HEPATOLOGY. 5:285-294.Full Text via DOI: 10.1016/S2468-1253(19)30327-9 PMID: 31953079
-
2020
-
2020Tumor downsizing following neoadjuvant therapy for borderline-resectable pancreatic adenocarcinoma. JOURNAL OF CLINICAL ONCOLOGY.
-
2018Residual Leukemia in the Bone Marrow and/or Peripheral Blood on Day 7 of Blinatumomab Therapy Predicts Response in B-Cell Acute Lymphoblastic Leukemia. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S237-S237.
-
2016Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment. CYTOTHERAPY. 18:653-663.Full Text via DOI: 10.1016/j.jcyt.2016.02.006 PMID: 27059202
-
2016A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only. ONCOLOGIST. 21:279-280.Full Text via DOI: 10.1634/theoncologist.2015-0439 PMID: 26911408
-
2016A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers. CANCER INVESTIGATION. 34:213-219.Full Text via DOI: 10.3109/07357907.2016.1174257 PMID: 27127841
-
2015Generation of Highly Cytotoxic Natural Killer Cells for Treatment of Acute Myelogenous Leukemia Using a Feeder-Free, Particle-Based Approach. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 21:632-639.Full Text via DOI: 10.1016/j.bbmt.2014.12.037 PMID: 25576425
-
2015In Vivo Expansion of NK Cells Stimulated with PM21 Particles Under Ultralow IL-2. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. S51-S51.
-
2012Bevacizumab, pertuzumab, and sandostatin for patients (pts) with advanced neuroendocrine cancers (NET). JOURNAL OF CLINICAL ONCOLOGY.
Background
Full Name
- Ahmed Zakari, MD
Education
- Georgetown University Medical Center, Washington D.C.
Residency
- The Brookdale University Hospital, Brooklyn, NY
Fellowship
- Georgetown University Medical Center, Washington, D.C.
Board Certification
- American Board of Internal Medicine
Contact
primary email
- Research.Institute@AdventHealth.com